Transplanting Future Revenue

The risk-benefit analysis for drugs can be one of the trickiest things for investors to determine. Unfortunately documents published ahead of Bristol-Myers Squibb's (NYSE: BMY  ) Food and Drug Administration advisory panel on Monday don't clear things up much.

The advantages of Bristol-Myers' potential kidney transplant drug, belatacept, are clear. According to Bristol-Myers, belatacept doesn't have the toxicity seen in Abbott Labs' (NYSE: ABT  ) Gengraf and Novartis' (NYSE: NVS  ) Sandimmune and Neoral. The FDA noted that more patients were alive two years after taking belatacept compared to the older medications.

But -- and there's always a but -- the drug isn't perfect. There were some complications with kidney rejections in some patients and cases of progressive multifocal leukoencephalopathy (PML) were also observed.

The risk of PML is always a concern for drugs that suppress the immune system because PML is caused by a viral infection. For some drugs, like Biogen Idec's (Nasdaq: BIIB  ) and Elan's (NYSE: ELN  ) Tysabri, the rewards of the drug are seen as justifying the risk. For others, like Genentech's Raptiva, they aren't.

We won't know which side of the question belatacept falls on until the committee votes Monday. Quantifying whether the benefits outweigh the risks is difficult enough for transplant doctors let alone those of us with far less experience.

Based on the FDA documents, I'd guess belatacept has a good chance of getting past the committee, but it's not a slam dunk. The agency doesn't have to follow the panel's advice, but given the complex nature of risk/benefit analysis, I expect the experts vote will weigh heavily when the agency makes its final decision on or around May 1.

Sit tight investors, there isn't much longer to wait.

Here are a few more drugmakers expecting FDA decisions this year.

Elan is a Motley Fool Rule Breakers pick. Novartis is a Global Gains selection. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1121720, ~/Articles/ArticleHandler.aspx, 9/22/2014 10:48:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement